Nov 1 (Reuters) - Bionomics Ltd BNO.AX :
* BIONOMICS RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF BNC210 IN A PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY
* BIONOMICS LTD - PREVAIL STUDY REMAINS ON TARGET TO INITIATE BY END OF 2021 AND IS EXPECTED TO READ OUT TOPLINE DATA BY END OF 2022
Source text for Eikon: ID:nPn3d6VMYa Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;))